C erebral venous sinus thrombosis (CVST) is a rare disorder with an estimated annual incidence of 3 to 4 cases per 2 million adults.
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The study was approved by the University Ethical Committee. The participants gave informed consent.
Laboratory Investigations
Fasting blood was drawn in the morning within the first 18 months since the diagnosis and at 1 to 5 months since anticoagulation withdrawal. Plasma D-dimer, plasminogen activator inhibitor-1 antigen and tissue-type plasminogen activator antigen were determined using immunoenzymatic assays (all; American Diagnostica Inc, Greenwich, CT). Thrombophilia screening was performed as described. 5, 6 Plasma clot permeability was assessed using a pressuredriven system and expressed as a permeation coefficient (K s ), which indicates the pore size in fibrin networks. [5] [6] [7] The lag phase of the turbidity curve and the maximum absorbance at the plateau phase (ΔAbs) were recorded. 5, 9 Clot lysis time induced by recombinant tissue-type plasminogen activator added to plasma with tissue factor and phospholipids was determined. 9 Moreover, D-dimer levels during tissue-type plasminogen activator-induced lysis were measured in the effluent up to the collapse of the plasma gel and maximum rate of increase in D-dimer (D-D rate ) with maximum D-dimer concentrations (D-D max ) were estimated. 5, 9 Fibrin variables were assessed by technicians blinded to the origin of samples. Interassay and intra-assay coefficients of variation were <8%. For details see the online-only Data Supplement.
Continuous variables were presented as a mean and standard deviation or a median (interquartile range). Categorical variables were presented as numbers (percentages 
Results
The CVST and control groups did not differ regarding CVST risk factors, except severe thrombophilia, including deficiencies of antithrombin (n=1), protein C (n=1), protein S (n=3), and antiphospholipid syndrome (n=5), that occurred more often in the CVST group. Factor V Leiden was also more common among patients with CVST. Fibrinogen, D-dimer, and plasminogen activator inhibitor-1 antigen were similar in both groups, whereas tissue-type plasminogen activator antigen was slightly lower in the patients ( (Figure) . No other recurrence-associated differences were noted (Tables  II and III in 
Discussion
This study is the first to demonstrate that faster formation of denser plasma fibrin clots displaying impaired lysability characterizes patients with CVST. Prothrombotic persistent changes observed after CVST were more pronounced compared with clot abnormalities reported in venous thromboembolism 5 and ischemic stroke. [6] [7] [8] They cannot be explained by fibrinogen concentrations and demographic/clinical factors. Higher prevalence of thrombophilia in CVST reported also in previous studies 1,2 might, in part, contribute to abnormal clot characteristics. 9 Importantly, denser clot structure expressed as D-D max may predict the recurrence of CVST, suggesting its prognostic value. Our study has limitations. The size of the study groups was limited particularly in the subgroup analysis. The results of our study cannot be likely extrapolated to elderly patients with CVST because patients at the age of ≥60 years were excluded from this study. Similarly, we ruled out individuals with previous thromboembolic events that are known to be associated with prothrombotic clot phenotype. 5, 10 The small difference in the duration of the lag phase of turbidimetric curves measured in the patients with CVST and controls is negligible, although statistically significant. All the parameters were analyzed after thrombosis, which might per se alter clot phenotype. 5 A common FXIII Val34Leu polymorphism which affects clot structure was not assessed.
10
Conclusions
This study identifies a potential new risk factor for CVST and its recurrence. Our study indicates that in some patients with CVST permanent prothrombotic features of fibrin clots, regardless of thrombophilic factors, could contribute to the occurrence of this disorder and predispose to its recurrence. It might be speculated that prolonged anticoagulation may be considered for patients with abnormal clot characteristics. However, interventional studies are needed to validate this hypothesis. 
Supplemental Methods
For fibrin analysis, blood was drawn from an antecubital vein with minimal stasis after an overnight fast between 8 to 10 AM. All fibrin variables were determined in citrated plasma in duplicate.
Clot permeation. Briefly, 20 mmol/L calcium chloride and 1 U/ml human thrombin (SigmaAldrich, St. Louis, MO, USA) were added to 120 μl of citrated plasma. After 2 hours of incubation in a wet chamber, tubes containing the clots were connected via plastic tube to a reservoir of a buffer (0.05 mol/L Tris, 0.1 mol/L NaCl, pH 7.5), and its volume flowing through the gels was measured within 60 minutes at the pressure of 4 cm of water. A permeation coefficient (Ks) was calculated from the equation: Ks=QxLxη/txAxΔp, where Q is the flow rate in time t; L, the length of a fibrin gel; η, the viscosity of liquid (in poise); A, the cross-sectional area (in dynes/ cm 2 ); t, percolating time. Ks (Darcy's constant) is a measure of the density of fibrin networks, which represents a mean surface of the average pore estimated using a pressure-driven system. The lower Ks, the more compact are fibrin networks. The intra-and interassay coefficients variation were 6.8 and 7.3%, respectively. Turbidity measurements. Plasma citrated samples were mixed 2:1 with a Tris buffer containing 0.6 U/mL human thrombin (Sigma-Aldrich, St. Louis, MO, USA) and 50 mM calcium chloride to initiate plasma polymerization. Absorbance was read at 405 nm with a Perkin-Elmer Lambda 4B spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). The lag phase of the turbidity curve, which reflects the time required for the initial protofibril formation and the maximum absorbance at 405 nm at the plateau phase (ΔAbs), indicating the number of protofibrils per fiber, were recorded. The interassay and intraassay coefficients of variation were 6.8% and 7.4% for the lag phase and 6.8% and 7.7% for ΔAbs, respectively Plasma clot lysis assays Assay 1. The efficiency of fibrinolysis was assessed using clot lysis time (CLT) assay. Citrated plasma was mixed with 15 mmol/L calcium chloride, 0.6 pmol/L (Innovin, Siemens, Marburg, Germany) human tissue factor, 12 μmol/L phospholipid vesicles and 60 ng/ml recombinant t-PA (rt-PA, Boehringer Ingelheim, Ingelheim, Germany). CLT was defined as the time from midpoint of the clear-to-maximum-turbid transition, to the midpoint of the maximum-turbid-to-clear transition. The coefficients of intra-and interassay variations were 5.2% and 5.8%, respectively. Assay 2. Fibrinolysis of the plasma clots formed as described above was assessed during their perfusion with the same buffer containing 0.2 μmol/L rtPA. D-dimer concentrations (American Diagnostica Inc, Greenwich, CT, USA) were measured every 20 min in the effluent up to collapse of the gel under the pressure. Maximum rate of increase in D-dimer (D-Drate) and maximum D-dimer concentrations (D-Dmax) were measured. The inter-and intraassay coefficients of variations were 6.8% and 7.4%, and 6.5% and 7.1%, respectively. Power calculation. The study was powered to have a 90% chance of detecting a 10% difference in CLT using a p-value of 0.01, based on the values of clot lysis time in the previous study.
1 In order to demonstrate such a difference or greater, 32 patients or more were required in each group. In turn, to demonstrate such a difference or greater in fibrin clot permeability using a p-value of 0.05 at least 31 were required in each group. 2 Given the inter-and intraassay coefficients of variations for fibrin variables, the intergroup difference of 10% or more in fibrin variables was selected as significant based on our previous studies in which the same methodological approach was used. Abbreviations see Table I . * after adjustment for fibrinogen
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